Fat pasmak ɛn di sik dɛm we gɛt fɔ du wit di mɛtabolik dɔn bi big prɔblɛm wit wɛlbɔdi biznɛs ɔlsay na di wɔl, ɛn dis dɔn mek pipul dɛn de luk fɔ mɔ tritmɛnt dɛn we go wok fayn. Pan di laytst nyu tin dɛm we dɛn dɔn mek pan weit-lɔs tritmɛnt dɛm, Retatrutid dɔn gɛt bɔku atɛnshɔn as prɔmis tripl-agonist drɔg. difrεnt frכm tradishכnal mεdikeshכn dεm fכ lכs wet, we de tכk to wan כ tu rεsεpכta dεm, dεn mek Retatrutid fכ aktibכt tri path dεm—GLP-1, GIP, εn glukagon rεsεpכta dεm—we de gi di pכtεnshal fכ εnhans weit rεdukshכn εn mεtabolik impruvmεnt. As di klinik trial dɛn de go bifo, bɔku pipul dɛn de tɔn dɛn atɛnshɔn naw to di kɔst fɔ retatrutide ɛn if i go izi fɔ di wan dɛn we nid am mɔ.
Tide, Retatrutid stil de na di invɛstigeshɔn faz ɛn dɛn nɔ dɔn gri fɔ yuz am yet fɔ yuz am ɔlsay, bɔt di fɔs klinik trial rizɔlt dɛn de ɛnkɔrej, we de sho se i gɛt bɔku bɛnifit fɔ lɔs dɛn wet fɔ pasɛnt dɛn we de strɛs wit fat ɛn ɔvaweit. Dis atikul de ɛksplɔrɔ di mɛkanism fɔ akshɔn biɛn Retatrutid, di kɔst naw fɔ risach-grɛd fɔmyulashɔn, ɛn wetin di fiuja go gɛt fɔ dis prɔmis tritmɛnt.
Wan pan di men rizin dɛm we mek Retatrutid dɔn atrak bɔku atɛnshɔn na in nyu tripl-agonist mɛkanism. difrεnt frכm tradishכnal tεrapi dεm we de fכkus pan wan mεtabolik tכgεt nכmכ, dεn mek Retatrutid fכ akt pan tri imכtant rεsεpכta dεm we lεnk to weit kכntrכl εn mεtabolik hεlth. Dis brayt mεkanism na wan pan di men rizin dεm we dεn kin tek am as prכmis nεks jεnereshכn tritmεnt.
· GLP-1 (Glucagon-Like Peptide-1)
Dɛn no GLP-1 mɔ fɔ ɛp fɔ ridyus di apɛtit ɛn sɔpɔt fɔ kɔntrol di blɔd shuga. I kin mek di gastric ɛmti slo, i kin mek dɛn fil lɛk se dɛn ful-ɔp, ɛn ɛp di sikman dɛn fɔ it smɔl as tɛm de go. biכs fכ dεn ifekt dεm ya, GLP-1 dכn כlrεdi bi wan imכtant rod fכ tritmεnt dεm we pipul dεn no fכ lכs weit lεk semaglutide.
· GIP (Gastric Inhibitory Polypeptide)
GIP de ple rol fכ insulin sekreshכn εn mεtabolik rεguleshכn. we dεn kכmbayn wit GLP-1 aktiviti, i kin mek wan strכng כvala mεtabolik rεspכns. Risach pipul dɛn biliv se dis kɔmbayn kin ɛp fɔ mek di tritmɛnt wok fayn pas wetin wan mɛrɛsin we de yuz wan rod kin ebul fɔ du.
· Glucagon
Glucagon de ad wan כda imכtant dimenshכn to Retatrutid in mεkanism. dis path de sho se di enεji we de spεnd pasmak εn fεt כksidεshכn, we min se i kin εp di bכdi fכ bכn mכr kalori insted fכ כnli ridyus di kalori we i de it.
· Wetin mek dis impɔtant Bay
we i de akt pan ɔl di tri rod dɛn wan tɛm, Retatrutid kin inflɔws di apɛtit, glukɔs mɛtabolism, ɛn ɛnaji yus mɔ kɔmprɛhnsiv wan pas di fɔs tritmɛnt dɛn. Dis na di rizin we mek bɔku pipul dɛn we de stɔdi bɔt dis kin si am as big tin we dɛn kin du fɔ mɛn pipul dɛn we fat. di εli Faz 2 stכdi dεm dεn dכn trכng intres bak, wit notabl weit-lכs risכlt dεm we dεn ripot ova 24 to 48 wiks.
difrεnt frכm singl-target drog dεm, we de fכkus pan wan spεsifi k mεtabolik path, Retatrutid in yכnik disayn de aim fכ maksimayz effektivnes bay we i de tכk bכt mכltipכl prכsεs dεm we de infכlכw weit lכs. Bɔku mɛrɛsin dɛn we de naw fɔ lɔs yu wet, lɛk GLP-1 riseptɔ agonist lɛk Ozempic ɛn Wegovy, dɔn pruv se dɛn wok fayn fɔ ridyus di apɛtit ɛn kɔntrol di blɔd shuga. כltu, dεn biliv se di kכmbaynshכn we Retatrutid gεt GLP-1, GIP, εn glukagon rεsεpכta dεm de gi mכr כlistik we fכ mεnεj di wet.
Insay Faz 2 trayal, Retatrutid sho wɔndaful rizɔlt fɔ lɔs wet. Akɔdin to di las data we Lilly bin pul, di wan dɛn we tek pat pan Retatrutid bin gɛt wan minin wet lɔs we go rich 24.2% we dɛn ol 48 wik, we rili ay pas wetin dɛn dɔn ajɔst wit ɔda tritmɛnt dɛn na di sem kayn trayal kɔndishɔn dɛn. Dɛn rizɔlt ya ɛp fɔ mek dɛn mek Retatrutid as wan pan di mɛrɛsin dɛn we de prɔmis fɔ mɛn pipul dɛn we fat pasmak.
We dɛn bil di sakrifays we di Faz 2 trayal dɛn gɛt, Lili dɔn ɔlrɛdi muf Retatrutid insay bɔku Faz 3 trayal dɛn fɔ ebul fɔ no aw i de wok ɛn sef akɔdin to bɔku pipul dɛn. Di Faz 3 stεdi dεm go εksplכr bak di lכng tεm ifekt dεm we di drog gεt εn in pכtεnshal bεnεfit dεm fכ mεnεj kכndishכn dεm lεk Tayp 2 mεtabolism, knee osteoarthritis, εn ivin slip apnea. Di fɔs ripɔt dɛn sho se Retatrutid kin ridyus di bɔdi wet bay pas 28% pan di wan dɛn we fat ɛn we gɛt ɔstiɔ-arayt na di ni. Dɛn tin ya we dɛn dɔn fɛn de gi op fɔ di wan dɛn we de sɔfa wit bɔku bɔku sik dɛn we nɔ de mɛn.
Bikɔs Retatrutid stil de na klinik trial, i nɔ de yet fɔ pɔblik sɛl ɔ prɛskrishɔn. Bɔt as intres pan di drɔg de gro, na so di kɔriɔs fɔ no bɔt di kɔst fɔ Retatrutid de gro. As wit bɔku invɛstigeshɔn drɔgs, di prayz we dɛn de pe naw fɔ di risach-grɛd Retatrutid kin difrɛn difrɛn wan dipen pan di spɔlayt ɛn di paket saiz.
Naw, Retatrutid de tru sεlekt pεptida spכlayt dεm we de gi am insay risach-grεd fכmyuleshכn. Dɛn prayz ya kin sho di kɔst fɔ yuz na lɛbɔretri pas fɔ yuz ful prɛskrishɔn mɛrɛsin. Di prayz fɔ risach-grɛd Retatrutid kin difrɛn bay di doz, wit dɛn aprɔksimat kɔst ya:
Sɔntin |
Di doz we dɛn fɔ yuz |
Ɔmɔs |
Kost (fɔ ɛni kit) . |
Retatrutid 10mg we yu de yuz |
10mg we yu de yuz |
1 kit (10 vayl) . |
$200.00 fɔ di mɔni |
Retatrutid 20mg we yu de yuz |
20mg we yu de yuz |
1 kit (10 vayl) . |
$320.00 fɔ di mɔni |
Retatrutid 30mg we yu de yuz |
30mg we yu de yuz |
1 kit (10 vayl) . |
$430.00 fɔ di mɔni |
Retatrutid 40mg we yu de yuz |
40mg we yu de yuz |
1 kit (10 vayl) . |
$480.00 fɔ di mɔni |
Retatrutid 50mg we yu de yuz |
50mg we yu de yuz |
1 kit (10 vayl) . |
$580.00 fɔ di mɔni |
As yu kin si, di retatrutide kɔst de go ɔp wit di doz, we de sho di kɔmplisiti we de gro pan di fɔmyulashɔn ɛn di yus we dɛn bin want fɔ yuz na klinik sɛtin. Bɔt dɛn prayz ya na fɔ risach nɔmɔ, ɛn di rial makit prays fɔ wan kɔmɛshɔnal vɛshɔn fɔ Retatrutid go mɔs difrɛn wans dɛn dɔn gri fɔ yuz am ɔlsay.
Wans Retatrutid gɛt FDA aprɔval ɛn go insay di kɔmɛshɔnal makit, di prayz go dipen pan sɔm tin dɛn, lɛk:
· Di kɔst fɔ mek di mɛrɛsin : Aw dɛn kin mek ɛn sheb di mɛrɛsin fayn fayn wan.
· Rigyuletɔri fi ɛn patɛnt protɛkshɔn : Di kɔst we gɛt fɔ du wit fɔ gɛt aprɔval ɛn fɔ mek dɛn gɛt rayt fɔ di drɔg nɔmɔ.
· Kɔmpitishɔn frɔm ɔda mɛrɛsin dɛn we de mek pɔsin in wet : Di prayz go afɛkt aw ɔda tritmɛnt dɛn, lɛk semaglutide ɔ tirzepatide, de du na di makit.
· Inshɔrans kɔvarej : If dɛn gri fɔ Retatrutid, aw inshɔrans kɔmni dɛn go kɔba in kɔst fɔ di sik pipul dɛn kin ple bak pan in ɔl prayz.
Given di prɔmis rizɔlt frɔm in Faz 2 trayal dɛm, Retatrutid gɛt di potenshal fɔ chenj di land skay fɔ weit lɔs tritmɛnt. If Faz 3 trayal dɛn kɔntinyu fɔ gi fayn fayn rizɔlt, ɛn di rigyuletɔri bɔdi dɛn gri fɔ di drɔg, i kin bi wan impɔtant kɔmpitishɔn to di tritmɛnt dɛn we dɔn de lɛk GLP-1 agonist ɛn bariatric ɔpreshɔn.
Bɔt pan ɔl we i tan lɛk se di mɛrɛsin go wok fayn, i impɔtant fɔ tek tɛm wit di tin dɛn we wi nɔ no—espɛshali we i kam pan di kɔst. Di retatrutide kɔst go dɔn ple wan impɔtant pat pan aw di tritmɛnt go izi fɔ di wan dɛn we nid am mɔ. Jɔs lɛk ɛni nyu drɔg, di wɛlbɔdi biznɛs sistɛm, di wan dɛn we de pe, ɛn di wan dɛn we de mek di polisi go nid fɔ balans di kɔst wit bɛnifit we dɛn de disayd aw fɔ intagret Retatrutid insay di tritmɛnt protɔkɔl dɛn.
As nyu triplɛ-agonist weit lɔs tritmɛnt, Retatrutid gɛt bɔku prɔmis fɔ pipul dɛn we de liv wit fat ɛn mɛtabolik dizayd. di ebul we i ebul fכ tכk tri imכtant mεtabolik path dεm de gi am wan yכnik edj pas כda weit-lכs tεrapi dεm. Bɔt bɔku pan di atɛnshɔn we de arawnd Retatrutid na bay in invɛstigeshɔn stetɔs, wit klinik trial dɛn we stil de go bifo fɔ fulɔp fɔ no in sef ɛn lɔng tɛm bɛnifit dɛn.
Pan ɔl we di retatrutide kɔst na di risach makit kin gi wi wan aidia bɔt di prayz rɛnj, di aktual kɔmɛshɔnal kɔst go mɔs bi inflɔws bay bɔku tin dɛn, frɔm manufakchurin to wɛlbɔdi polisi. Fɔ naw, ɛnibɔdi we want fɔ no mɔ bɔt dis tritmɛnt ɔ fɔ de ɔpdet bɔt aw i de go bifo fɔ tink bɔt fɔ kip in yay pan di klinik data we de kɔmɔt frɔm di trial dɛm we i dɔn gɛt.
Na Cocer Peptides Co., Ltd. , wi de fala di divɛlɔpmɛnt dɛm fɔ prɔmis tritmɛnt dɛm lɛk Retatrutid klos wan. Wi komitmɛnt fɔ gi ay kwaliti peptide ɛn famasi-grɛd prodakt min se wi kin gi valyu insayt fɔ di peptide makɛt ɛn in evolving land skay. Fɔ di wan dɛn we want fɔ ɔndastand mɔ bɔt Retatrutid, ilɛksɛf na fɔ risach ɔ fɔ yuz di tritmɛnt tumara bambay, wi de ɛnkɔrej yu fɔ no mɔ bay we yu fala di ɔpdet dɛn na di industri ɛn rich to wi fɔ gɛt ditayla infɔmeshɔn bɔt di prɔdak.
Retatrutid na tripl-agonist, we min se i de target tri mεtabolik path dεm—GLP-1, GIP, εn glucagon—we de gi wan brayt mεkanism fכ akshכn we yu kכmpεr wit כda weit-lכs drog dεm lεk GLP-1 agonist dεm. Dis mכlti-target apכch kin pכtεnshal fכ gi εnhans weit lכs εn mεtabolik bεnεfit.
Bikɔs Retatrutid stil de na klinik trial, di wangren prayz we de na fɔ risach-grɛd fɔmyulashɔn. Risach prayz de frɔm $200 fɔ 10mg to $580 fɔ 50mg fɔ wan 10-vial kit. Prays kin difrɛn akɔdin to di saplay ɛn fɔmyulashɔn.
Naw, Retatrutid stil de na Faz 3 klinik trial ɛn i nɔ gɛt FDA aprɔval yet. Di tɛmlayn fɔ in kɔmɛshɔnal avaylabl dipen pan di autkam fɔ dɛn trayal ya ɛn rigyuletɔri rivyu.
rεtatrutid de wok bay we i de tכk tri ki rεsεpכta dεm we de involv fכ lכs di wet: GLP-1 fכ apεtit rεgulεshכn, GIP fכ glukכs mεtabolism, εn glukagon fכ εnεji εkspεndishכn. dis tripl-target apכch dεn de εkspεkt fכ gi wan mכr kכmprεhεnsiv sכlushכn fכ weit mεnejmεnt.
